Introduction {#Sec1}
============

Atherosclerosis is an inflammatory and systemic disease \[[@CR1]--[@CR3]\]. A key process that initiates the development of atherosclerosis is an endothelial dysfunction, followed by lipid accumulation, the recruitment of macrophages and T-lymphocytes as well as the migration and proliferation of smooth muscle cells in the vascular wall. Additionally, the regeneration potential of endothelial progenitor cells is diminished because of their reduced number and impaired function \[[@CR2]\]. The resultant impaired vasorelaxation and the expansion of the vascular wall impede the laminar blood stream, which promotes the thrombus formation. The consequent plaque rupture and the activated coagulation system may lead to complete stenosis of an affected vessel with consecutive infarction of the correspondent tissue \[[@CR3]\]. Besides known main risk factors for development of atherosclerosis such as hypertension, diabetes mellitus, hypercholesterolemia, nicotine abuse, obesity, age and male sex, sleep apnoea syndrome have been reported to have an independent negative impact on the vascular structure and function.

The obstructive sleep apnoea (OSA) is characterised by a repetitive partial or complete collapse of upper airways during sleep terminated by arousals with consecutive repetitive hypoxia/reoxygenation phases. In contrast to central apnoea syndrome, the obstructive one is associated with inefficient breath efforts \[[@CR4]--[@CR9]\]. The obstructive sleep apnoea syndrome is defined as more than five apnoeas (no breath flow for more than 10 s)/hypopnoea (reduced breath flow) per hour (so called apnoea/hypopnoea index: AHI) in polysomnography accompanied by the following symptoms: loud snoring, breathing stoppage, nocturia, headache, excessive daytime sleepiness and deficits in memory and attention with subsequent risk of accident by day. According to the actual data, about 20% and 7% of adults suffer from mild OSA (5/h \< AHI \< 15/h) and moderate to severe OSA (AHI \> 15/h), respectively. The nocturnal hyperpressure treatment, so-called CPAP (continuous positive airway pressure) ventilation is the gold-standard therapy of OSA. It consists in creating of pneumatic track that avoids the collapse of the upper airways. However, a relevant number of patients does not tolerate CPAP therapy \[[@CR10]\], which implicates necessity of searching for alterative therapy options. Moreover, it is not clear, which group of OSA patients should be treated. It seems that the genetic predisposition which influences the extent of vascular responses to OSA-related pathological changes and coexistence of independent cardiovascular risk factors determine patients at particularly high cardiovascular risk. Because of that, the identification of such patients is one of the most important issues when deciding about OSA therapy. The estimation of individual risk constellation should be a basis for an optimal personalised OSA treatment.

Possible pathomechanisms linking OSA with atherosclerosis {#Sec2}
=========================================================

A growing body of evidence associates OSA with development of atherosclerosis \[[@CR4]--[@CR9]\]. A key phenomenon which is believed to initiate the atherosclerotic vessel changes is the intermittent hypopnoea-related disturbance of vascular micromilieu. Because OSA is often attended by other comorbidities which are also risk factors for atherosclerosis formation, it is sometimes difficult to understand the exclusive impact of OSA on vascular diseases. Nevertheless, a lot of controlled, methodically excellent studies have demonstrated that different neural, vascular, mechanic, inflammatory and metabolic mechanisms discussed below may be activated in OSA (Fig. [1](#Fig1){ref-type="fig"}): Neural activity: stimulation of sympathetic nerves with consequent release of catecholamine substances in the blood plasma and the urine \[[@CR11]\].Vascular changes: overproduction of vasoconstrictors like endothelin in relation to reduced release of vasorelaxants, such as NO \[[@CR12]--[@CR14]\]; detection of elevated oxidative stress \[[@CR15]\], reduced endothelium-dependent vasodilatation due to impaired function of endothelial cells \[[@CR16]\].Mechanical factors: fluctuation of intrathoracic pressure via increase in blood pressure may enhance shear stress in the vessel wall with subsequent diastolic dysfunction \[[@CR17]\].Inflammatory mediators: cytokines and adhesion molecules attract leukocytes to the endothelial layer, which promotes atherosclerosis in OSA \[[@CR18]--[@CR20]\]. Elevated inflammatory markers, such as C-reactive protein (CRP), serum amyloid A were demonstrated to be negative predictor markers for cardiovascular endpoints \[[@CR21], [@CR22]\]; the CRP levels were increased among children with OSA, irrespective of body weight \[[@CR23]\]; other study showed high CRP concentration only in obese OSA patients \[[@CR24]\].Circulating endothelial progenitor cells as regeneration capacity marker are reduced in OSA patients \[[@CR25]\]. In contrast, the number of circulating apoptotic endothelial cells increases as indicator for endothelial dysfunction \[[@CR26], [@CR27]\]. The last one correlates positively with the AHI degree \[[@CR28]\].Hypercoagulability: elevation of fibrinogen, haematocrit, plasminogen activator inhibitor-1 and platelet aggregation \[[@CR7], [@CR29]\].Metabolic changes: obesity is closely associated with OSA. It was described as a cause of OSA, but it can also be worsen by OSA. The patients with new diagnosed OSA had a significant weight increase 1 year prior diagnosis of OSA compared to similar adipose patients without OSA \[[@CR30]\]. Moreover, the CPAP therapy induces fat redistribution with reduction of subcutaneous and visceral fat \[[@CR31]\]. Many studies have linked obesity to oxidative stress and inflammation underlying endothelial dysfunction. However, the presence of OSA in these studies was not systematically excluded. Recently, it has been shown that OSA rather than obesity may be predominantly responsible for increased oxidative stress, inflammation and endothelial impairment \[[@CR32]\].Fig. 1Pathophysiological interactions between OSA and atherosclerosis. The OSA-associated effects (*top*) initiate different pathomechanisms (*left*) that contribute to the development of atherosclerosis (*down*). Defined risk factors (*right*) augment the atherosclerotic changes underlying vascular diseases (*down*)

The metabolic deregulation in OSA may be connected to the impaired leptin secretion. The increased levels of leptin in OSA in comparison with weight-adjusted patients without OSA may influence the breath control centre. Additionally, leptin may enhance the rate of cardiovascular events via stimulation of sympathetic activity and platelet aggregation \[[@CR33]\].

Moreover, the appetite and body fat regulators such as neuroleptid G and ghrelin are upregulated in OSA \[[@CR34]\].

The OSA patients suffer often from metabolic syndrome that comprises obesity, hypertension, increased levels of triglycerides and glucose and decreased levels of HDL-cholesterol \[[@CR35], [@CR36]\]. Insulin resistance and diabetes mellitus, irrespective of obesity, are related to OSA degree \[[@CR37], [@CR38]\]. Additionally, hypoxia-induced insulin resistance has been demonstrated in an animal model \[[@CR39]\]. Moreover, hypertension is widely accepted effect of OSA \[[@CR4]--[@CR9]\].

The most of the described pathomechanisms in OSA are positively influenced by CPAP therapy \[[@CR4]--[@CR9], [@CR25], [@CR28]\].

Epidemiological and clinical studies associating OSA with atherosclerotic disease {#Sec3}
=================================================================================

OSA is associated with coronary heart disease, myocardial infarction, ischaemic brain infarction, aorta dissection, hypertension, heart failure, erectile dysfunction, atrial fibrillation and sudden cardiac death. It is difficult to answer if OSA alone can act atherosclerotic, because the most OSA patients have additional atherosclerotic risk factors such as obesity, hypertension, hypercholesterolemia, insulin resistance and hyperglycaemia.

However, some animal and human studies attempted to demonstrate the direct link between OSA and atherosclerosis. Atherosclerosis could be induced in a mouse model of hypoxia on a cholesterol rich diet \[[@CR40]\]. Moreover, the patients with OSA have increased intima-media thickness (IMT) of a carotid artery, enhanced pulse wave velocity (PWV) between carotid and femoralis artery \[[@CR41]\] and increased coronary artery calcification in an electron beam tomography (EBCT) \[[@CR42]\]. The above parameters are early markers of atherosclerosis. A small study could also show a reduction of IMT and PWV under CPAP therapy \[[@CR43]\]. However, there are discrepant data concerning OSA and early atherosclerotic parameters, namely some studies could not demonstrate any association between OSA and IMT \[[@CR44]\].

Impact of OSA on coronary artery disease/myocardial infarction {#Sec4}
==============================================================

The prevalence of OSA in coronary artery disease is about two to three times higher compared to similar population without cardiovascular diseases. Oppositely, one can find OSA in 31--50% patients with angiographic documented coronary artery disease \[[@CR4]--[@CR9]\]. Although further studies have also demonstrated an association between OSA and coronary artery disease (Table [1a](#Tab1){ref-type="table"}), their data are limited by study design with small patient number and lack of controls \[[@CR45]--[@CR52]\]. Table 1Review of important epidemiological studies concerning a) OSA and b) effects of CPAP therapy in OSA. ACS - acute coronary syndrome, AHI - Apnoe-Hypopnoe-Index, CPAP - continuous positive airway pressure, ISR - In-Stent-Restenosis, MACE - major adverse cardiac events, MACCE - major adverse cardiac or cerebrovascular events, OR - Odds-Ratio, OSA - obstructive sleep apnoea, PCI - percutaneous coronary intervention, TIA - transitoric ischemic attackAuthorNumber of patientsCharacteristicsFollow-up (months)Results**a) Epidemiological studies** Schäfer et al. 1999 \[[@CR42]\]289AHI ≥ 20/h--Elevated risk for myocardial infarction: OR 2.0 Mooe et al. 2001 \[[@CR43]\]408AHI \> 1061Elevated risk for death, myocardial infarction and cerebrovascular events: OR 1.6 Shahar et al. 2001 \[[@CR44]\]6,424----Elevated risk for ischaemic brain infraction and coronary artery disease: OR 1.6 und 1.3, in each case the highest and the lowest AHI-quartile Marin et al. 2005 \[[@CR45]\]1,651AHI \> 30/h121More frequent lethal and non-lethal cardiovascular events: OR 2.9 und 3.2 Arzt et al. 2005 \[[@CR46]\]2,664AHI \> 20/h48Elevated risk for ischaemic brain infraction: OR 4.3, no significantly elevated risk for the first event Yaggi et al. 2005 \[[@CR47]\]1,022AHI ≥ 541Elevated risk for ischaemic brain infraction/death: OR 2.0 Yumino et al. 2007 \[[@CR48]\]89AHI ≥ 10/h + ACS/PCI8Elevated risk for MACE: OR 11.6 and binary ISR: 37 vs. 15% Valham et al. 2008 \[[@CR49]\]392AHI \> 5+ coronary artery disease120Elevated risk for ischaemic brain infraction: OR 2.9, no effect on myocardial infarction or death**b) Studies with CPAP therapy** Doherty et al. 2005 \[[@CR50]\]168AHI \> 15/h91Reduction of cardiovascular death: 15 vs. 19%, reduction of death/coronary artery disease: 18 vs. 31%, no effect on ischaemic brain infarction Milleron et al. 2004 \[[@CR51]\]54AHI ≥ 15/h + coronary artery disease87Reduction of cardiovascular death, ACS, hospitalisation from heart failure, revascularisation: OR 0.24 Marin et al. 2005 \[[@CR45]\]1,651AHI \> 30121Reduction of lethal and non-lethal cardiovascular events: OR 1.1 und 1.4 vs. healthy individuals Martinez-Garzia et al. 2005 \[[@CR52]\]95AHI ≥ 20/h + ischaemic brain infarction/TIA18Reduction of new vascular events: 7 vs. 36% Buchner et al. 2007 \[[@CR53]\]449AHI ≥ 572Reduction of cardiovascular events (myocardial infarction, ischaemic brain infarction, ACS, revascularisation): OR 0.36 Cassar et al. 2008 \[[@CR54]\]371AHI ≥ 15/h + PCI60Reduction of cardiovascular death: 3 vs. 10%, no differences for MACE, MACC Doherty et al. 2005 \[[@CR50]\]168AHI \> 15/h91Reduction of cardiovascular death: 15 vs. 19%, reduction of death/coronary artery disease: 18 vs. 31%, no effect on ischaemic brain infarction

The most important prospective observational study by Marin et al. demonstrated that patients with an untreated severe OSA suffer more frequently from myocardial infarction and stroke than patients without OSA in a time frame of 10 years \[[@CR48]\]. Additionally, the CPAP therapy could prevent the above vascular endpoints in the study. However, also this study must be interpreted carefully, because the results of non randomised behavioural studies can not always be confirmed in subsequent randomised studies. This fact depends for example on higher health awareness and/or better compliance of patients who accept CPAP therapy.

In contrast to the study of Martin et al., a community-based prospective cohort study of the cardiovascular consequences of OSA \[[@CR53]\] demonstrated that the association of OSA with incident coronary heart disease after adjustment for other risk factors is much weaker and of no statistical significance. These discrepancies could be explained by older age of the cohort, as OSA-related cardiovascular risk decreases with age. Another finding of Gottlieb et al. was that OSA is a significant independent predictor of incident heart failure in men but not in women \[[@CR53]\]. However, it is not clear, if sex differences may reflect a protective effect of a female sex against cardiovascular risk or may be only a result of a statistical underestimation because of lower prevalence of women with severe OSA and later age of onset of OSA in women than in men.

The positive influence of CPAP therapy on cardiovascular endpoints was shown in further studies \[[@CR54]--[@CR58] Table [1b](#Tab1){ref-type="table"}\]. It was demonstrated that an effective CPAP therapy can reduce nocturnal cardiac ischemia/ST-segment elevations by cardiologic patients \[[@CR59]\].

Unfortunately, OSA appears to be strongly under diagnosed in patients with myocardial infarction, which probably results from persistent low awareness of OSA as a potential risk factor in cardiovascular patients \[[@CR60]\].

OSA as a risk factor for ischaemic brain infarction {#Sec5}
===================================================

Sleep-associated disorders can be found in approximately 2/3 cases of ischaemic brain infarction; while obstructive sleep apnoea may be responsible for onset of ischaemic brain infarction, the central one can be an effect of stroke \[[@CR61]\]. The genesis of OSA-associated ischaemic insult is probably the result of multiple factors: atherosclerotic plaques in brain vessels, hypertension, thrombembolic events based on atrial fibrillation, paradoxical embolism via enhanced right-left shunts by persistent foramen ovale. Moreover, OSA may disturb the cerebral autoregulation \[[@CR62]\]. Lately, the association between microembolisms detected in MRT and OSA has been demonstrated \[[@CR63]\]. A prospective study based on the questionnaire showed that snoring may be an independent risk factor for ischaemic insult \[[@CR64]\]. Other studies were mostly cross-sectional or case-controlled that included only those patients who survived the cerebral insult \[[@CR50]--[@CR52], [@CR56] Table [1](#Tab1){ref-type="table"}\]. Yaggi et al. demonstrated increased stroke rates in OSA patients in a longitudinal study, but in contrast to Marin et al. \[[@CR48]\], they could not show any positive effects of CPAP therapy on the reduction of stroke incidence \[[@CR50]\]. The explanation of this fact could be a low CPAP tolerance and reduced patients' compliance. Finally, another study concerning OSA patients after stroke event showed that CPAP therapy reduced the cerebral re-infarction rate as compared to untreated patients.

Potential diagnostic biomarkers for prediction and prevention of OSA-associated atherosclerosis {#Sec6}
===============================================================================================

Identification of OSA patients at a significant risk for the development of atherosclerosis is mandatory in order to prevent or at least to delay the occurrence of the vessel disease. It is known that similar degree of OSA severity may induce wide spectrum of atherosclerotic changes in different patients. It can be explained by interindividual differences in response to intermittent hypoxia which may mirror congenital or acquired disposition to disease or protective and regenerative potential. In order to anticipate if protective or deleterious mechanisms possibly predominate, several determinants have been proposed to serve as predictive biomarkers of the disease (Fig. [2](#Fig2){ref-type="fig"}). Besides direct changes in vessel structure and elasticity indicated by increase in arterial stiffness, intima/media thickness and atherosclerotic plaque volume which are already detectable in only minimal symptomatic OSA patients and are considered to be early markers of atherosclerosis \[[@CR43], [@CR65], [@CR66]\], alternations in number and function of different blood cells and cytokines have been examined for their utility as biomarkers of atherosclerosis. An example of such a biomarker may be leukotriene B~4~ which production is upregulated in OSA indicating its role as an incipient mediator of atherosclerosis \[[@CR67]\]. A number of further proinflammatory transcription factors and agents such as nuclear factor kappa B (NFkB), CRP, interleukin (il)-6, tumour necrosis factor (TNF)-alpha, intracellular adhesion molecule (ICAM)-1, vascular adhesion molecule (VCAM)-1, L-selectin, E-selectin, P-selectin and CD40 ligand as well as antioxidant genes \[[@CR68]--[@CR79]\] are elevated in OSA and play an important role in various stages of atherosclerosis. Moreover, decrease in anti-inflammatory acting interleukin-10 plasma levels predisposes to progression of atherosclerosis \[[@CR80], [@CR81]\]. Early inflammatory responses underlying atherosclerosis may be partly triggered by lipid accumulation in arterial wall as a result of decreased lipoprotein lipase activity found in OSA \[[@CR82]\]. Conversely, inflammation und oxidative stress lead to metabolic disorders accelerating atherosclerotic changes underlying end organ damage \[[@CR83]--[@CR85]\]. Another OSA-associated disorder that contributes to the progression of vessel lesions is the unbalance between vasoactive substances such as nitric oxide (NO) and endothelin (ET)-1 \[[@CR86]\], partly as a consequence of the overexpression of asymmetric dimethylarginine (ADMA) - endogenous inhibitor of NO production \[[@CR87]\] observed in OSA. Furthermore, some studies suggested OSA-related upregulation of hypoxia-inducible factor (HIF) 1 alpha followed by the exaggerated release of proatherogenic substances like vascular endothelial growth factor (VEGF) and ET-1 \[[@CR86], [@CR88]\]. Additionally, serum amyloid A and myeloid-related protein 8/14 which are linked to augmented risk for cardiovascular morbidity may be also elevated in OSA \[[@CR22], [@CR89]\]. Likewise, cellular changes in blood may indicate later atherosclerotic vessel alternations in OSA. For instance, an attenuated apoptotic index of neutrophils with subsequent disturbance of injury limiting mechanisms demonstrated in OSA may help identify patients prone to cardiovascular pathologies \[[@CR90]\]. Beyond that, OSA-induced hypoxic stress enhances invasive ability of monocytes, which may provide evidence for a raised risk for atherosclerosis development \[[@CR91]\]. Another phenomenon occurring in OSA which accelerates atherosclerosis is the increased lipid accumulation in macrophages \[[@CR92]\]. Lymphocyte activation with augmented cytotoxicity and cytokine imbalance in CD4 and CD8 T cells in OSA may also modulate some atherogenic pathways \[[@CR93]\]. Higher numbers of circulating endothelial (Annexin-V positive), platelet and leukocyte apoptotic microparticles combined with diminished endothelial progenitor cell count indicating disturbed endothelial repair mechanisms are believed to be further biomarkers for atherosclerosis in OSA \[[@CR94]--[@CR97]\]. Perspectively, molecular studies on the telomere length, which is thought to reflect cumulative burden of oxidative stress and inflammation in OSA, may contribute to improvement of cardiovascular risk estimation in OSA patients \[[@CR98]\]. Summarising, the risk stratification for the development of atherosclerosis in OSA by means of different biomarkers enables better monitoring of disease dynamics and, if required, early treatment initialisation. Fig. 2Cardiovascular risk estimation by means of different biomarkers

Standard and innovative therapy options {#Sec7}
=======================================

Once OSA has been diagnosed, the decision of therapy start and treatment options depends on the polysomnography results, including severity of OSA, clinical symptoms, comorbidities and patients' compliance. General therapy recommendations comprise common and sleep hygienic means, body weight reduction, physical activity, avoidance of alcohol and nicotine, training of sleep position, intraoral protrusion splints and operative methods. The gold standard is CPAP therapy, however the threshold value of AH-Index for therapy start is not known. Figure [3](#Fig3){ref-type="fig"} shows therapeutic procedures in OSA that have not been tested in randomised trials and which must be optimised for individual patients. In particular, OSA patients at elevated risk for cardiovascular diseases benefit mostly from early diagnosis and appropriate treatment. However, the recognition of such patients is not easy as there are no standardised criteria for cardiovascular risk stratification in OSA. Many biomarkers described above have been proposed to be a useful tool for anticipation of a vessel disease. Further randomised studies are needed to prove their clinical relevance. Fig. 3Therapeutic procedures in OSA according to the degree of OSA and accompanied symptoms and risk factors. AHI - Apnoe-Hypopnoe-Index, CPAP - continuous positive airway pressure

Although the mainstay of therapy in OSA is a treatment with CPAP, the targeted therapy of concomitant, independent of OSA cardiovascular risk factors is at least of the same importance. Therefore, the primary and secondary prevention of the known predisposing factors for the development of atherosclerosis such as hypertension, diabetes, dyslipidemia by accurate screening, efficient therapy and frequent controls improves the effectiveness of CPAP therapy in minimising of the atherosclerosis risk.

Since the adherence to CPAP therapy for OSA is poor \[[@CR10]\] and CPAP treatment does not eliminate all hypoxia-associated risk factors for atherosclerosis \[[@CR99]\], many study designs have focused on the development of alternative therapies. Besides the introduction of improved forms of positive airway pressure therapies \[[@CR100]\] and innovative devices such as electrical stimulator of the hypoglossal nerve \[[@CR101]\], different pharmacological interventions have been tested. Based on the hypothesis that OSA mediates its proatherogenic effects via induction of oxidative stress, the antioxidant strategies such as the intravenous infusion of antioxidant vitamin C in OSA subjects have been demonstrated to improve endothelial function \[[@CR102]\]. Investigations in the field of the involvement of the endothelin system in cardiovascular pathologies associated with OSA showed the beneficial cardiovascular effects of bosentan, a mixed endothelin antagonist, in OSA \[[@CR88]\]. In a subgroup of patients with both OSA and hyperlipidemia, targeting of a sterol regulatory element binding protein (SREBP)-1, a transcription factor for lipid biosynthesis, which is upregulated in OSA, could improve lipid metabolism and in consequence cardiovascular prognosis \[[@CR103]\]. Future studies are mandatory to prove attractive therapy concepts such as administration of anti-inflammatory substances, restoration of endothelial repair capacity via treatment with endothelial progenitor cells or molecular approaches taking into consideration genetically defined polymorphisms for prooxidant and antioxidant enzymes determining individual susceptibility to cardiovascular changes in OSA.

Perspectives {#Sec8}
============

Despite coexistence of not homogenous study results and problems by establishment of a good study design because of confusing factors, there are many convincing data demonstrating that obstructive sleep apnoea may influence negatively the development of atherosclerosis. Therefore, higher awareness in recognising of OSA, early diagnosis and effective therapy of OSA are indispensible elements of an appropriate medical care, particularly in patients at cardiovascular risk. Future directions comprise further studies on the mechanisms of cardiovascular damage in OSA in order to find new biomarkers of atherosclerosis characterised by their simplicity, noninvasivness and combined high sensitivity and specificity as well as to develop alternative therapy modalities. The knowledge of individual risk factors and different possible cardiovascular responses to the intermittent hypoxia will help improve personalised treatment.
